Neoleukin Therapeutics Inc (NLTX) stock is higher by 3.96% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.
Neoleukin Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on NLTX!
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With NLTX Stock Today?
Neoleukin Therapeutics Inc (NLTX) stock is lower by -3.72% while the S&P 500 is higher by 1.06% as of 1:51 PM on Monday, Sep 12. NLTX is down -$0.04 from the previous closing price of $1.09 on volume of 106,115 shares. Over the past year the S&P 500 has fallen -8.02% while NLTX is down -86.31%. NLTX lost -$1.12 per share in the over the last 12 months.
To see InvestorsObserver's Sentiment Score for Neoleukin Therapeutics Inc click here.
More About Neoleukin Therapeutics Inc
Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.
Click Here to get the full Stock Report for Neoleukin Therapeutics Inc stock.